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Abstract 
MicroRNA-15a (miR-15a)  and  miR-16,  which  are  transcribed  from  the miR-15a/miR-16-  
1 cluster, inhibit post-ischemic angiogenesis. miR binding to mRNA coding sequences (CDS) is 
a newly emerging mechanism of gene expression regulation. 
We aimed to 1) identify new mediators of the anti-angiogenic action of miR-15a and -16; 
2) develop an adenoviral-based (Ad) miR-15a/16 decoy system carrying a luciferase reporter 
(Luc) to both “sense” and  inhibit  miR-15a/-16  activity; 3)  investigate Ad.Luc-Decoy-  
15a/16 therapeutic potential in a mouse limb ischemia (LI) model. 
LI increased miR-15a and -16 expression in mouse muscular endothelial cells (ECs). The miRs 
also increased in cultured human ECs (HUVECs) exposed to serum starvation, but not hypoxia. 
Using bioinformatics tools and luciferase activity assays, we characterized miR-15a and -16 
binding to Tie2 CDS. In HUVECs, miR-15a or -16 overexpression reduced Tie2 at protein but 
not mRNA levels. Conversely, miR-15a or -16 inhibition improved angiogenesis in a Tie2- 
dependent manner. Local Ad.Luc-Decoy-15a/16 delivery increased Tie2 levels in ischemic 
skeletal muscle and improved post-LI angiogenesis and perfusion recovery, with reduced toe 
necrosis. Bioluminescent  imaging  (IVIS)  provided  evidence  that  the Ad.Luc-Decoy-  
15a/16 system responds to miR-15a/16 increases. 
In conclusion, we have provided novel mechanistic evidence of the therapeutic potential of 
local miR-15a/-16 inhibition in LI. 
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1 Introduction 
2 Peripheral artery disease affects 20% of individuals over 70 years of age worldwide1,2 and can 
3 result in critical  limb  ischemia  (CLI),  a  debilitating  condition characterized by  pain at rest, 
4 tissue loss and gangrene. The current management of CLI involves revascularization of the 
5 affected limb by percutaneous angioplasty or surgical bypass. However, many CLI patients are 
6 not suitable for revascularization for reasons such as severe comorbidities or late diagnosis. 
7 In approximately 30% of severely affected patients, minor or major amputations are 
8 inevitable3. Novel therapeutics to locally promote angiogenesis, and hence reperfusion, 
9 would help to overcome a significant unmet clinical need. 
 
10 Historically, human clinical trials have been informed by pre-clinical studies based on the 
11 delivery of single pro-angiogenic growth factors of the VEGF and FGF families4,5. Such 
12 approaches have not yet yielded the desired results6, 7. To reach the bedside of CLI patients, 
13 angiogenic therapies require further refinement, including revisiting the realm of therapeutic 
14 targets and their mechanisms of action8. 
 
15 MicroRNAs (miRNAs; miRs) are small non-coding RNAs that, in their mature form, act at the 
16 post-transcriptional level by targeting multiple mRNAs9. miRs are transcribed as a primary 
17 mRNA transcript (pri-miR), from miR genes or intronic regions of protein coding genes, and 
18 are subsequently processed to reach their mature and functional status10. The initial and 
19 canonical model of miRNA-induced mRNA silencing activity relies on semi-complementary 
20 binding between the miR seed sequence of 7-nucleotides to miR binding sequences contained 
21 in the 3’ untranslated region (3’UTR) of target mRNAs. However, it is becoming increasingly 
22 evident that miRNA binding to 5’UTR and coding sequences (CDS) of mRNAs have powerful 
23 functional consequences11. Each miRNA can target up to several hundred genes and multiple 
24 pathways and miRNAs are known to be involved in the regulation of a plethora of cellular 
25 processes, including angiogenesis12. Additionally, functionally active miRNAs are released 
26 from parent cells and taken up by bordering and possibly distant cells13, where they can 
27 repress their target genes, thus providing a widespread method of gene expression 
28 regulation. Investigations based on individual miRNA experiments have identified miRNAs 
29 with either proangiogenic or antiangiogenic effects14, 15. 
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30 MiR-15 and miR-16 are organized in two different clusters, miR-15a/16-1 and miR-15b/16-2, 
31 and are conserved between humans and mice16. The sequences of mature miR-15a and miR- 
32 15b differ by four nucleotides16, while miR-16-1 and miR-16-2 have the same mature 
33 sequence, hence are commonly indicated as miR-16. MiR-15a/b and -16 belong to the miR- 
34 16 family consisting of miR-15a, miR-15b, miR-16, miR-195, miR-424, and miR-497. The family 
35 is extendable to miR-103, miR-107, miR-646 and miR-503 due to homologies in the seed 
36 sequences17. The extended miR-16 family is involved in angiogenesis regulation: miR-16 
37 targets VEGF receptor 2 and FGF receptor 1, thus decreasing the proangiogenic activity of 
38 their ligands18. Moreover, following limb ischemia (LI), therapeutic angiogenesis is impaired 
39 in mice  with miR-15a  gene  knock-in19.  We  previously  described that miR-15a  and -16 are 
40 increased in both the proangiogenic circulating cells (PACs) and the serum of CLI patients (vs. 
41 healthy subjects). We also showed that serum concentrations of miR-15a and miR-16 predict 
42 the need for amputation at one year from revascularization in CLI subjects20. In further 
43 support of the relevance of miR-15a and miR-16 in the CLI setting, we provided evidence that 
44 ex vivo transfection with miR-15a/16 inhibitors increase the potential of human PACs to 
45 induce therapeutic angiogenesis in an immunocompromised mouse limb ischemia model20. 
 
46 Amongst the different ways to inhibit miRNA, the use of miR decoys, or “sponges”, that 
47 consist in multiple specific miRNA-binding site sequences inserted downstream of a reporter 
48 gene, represents a promising approach21-24. Using a decoy for the diabetes-associated miR- 
49 503, we have already provided proof-of-concept that adenovirus (Ad)-mediated local delivery 
50 of miR-decoy can improve post-ischemic angiogenesis and blood flow recovery in mice with 
51 limb ischemia23, 24. When delivered into cells, the binding of the targeted miR to the decoy 
52 sequences not only inhibit the miR by sequestration, but also reduce the expression of the 
53 reporter gene used, often eGFP22 or luciferase25. This construct could therefore be used as a 
54 sensor of the targeted miR quantity as the protein activity of the reporter used, is inversely 
55 correlated to the presence of the miR26, 27. Additionally, more recent technological 
56 advancements allow non-invasive and precise measurement of luciferase activity in vivo in 
57 mice28, 29. On these bases, we reasoned that Ad-mediated local delivery of a double miR- 
58 15a/16 decoy could provide therapeutic advantages by ensuring release from miR inhibition 
59 in a spatiotemporal defined window that is supportive for post-ischemic vascular repair. 
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60 This study was designed to mechanistically investigate the anti-angiogenic effect of miR- 
61 15a/16 and to develop an Ad.miR-15a/16 decoy to be tested for its therapeutic potential, in 
62 a mouse limb ischemia model. 
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63 Results 
64 miR-15 and -16 expression in human and mouse tissue 
 
65 Expression of miR-15a/b and miR-16 was assessed by RT-qPCR in 19 different human tissues. 
66 As shown in Figure 1 A-D, skeletal muscle showed the highest expression miR-15a and was 
67 the tissue with the 3rd highest expression of miR-16, after adipose and prostate tissues. 
68 Skeletal muscle was the 5th highest localization of miR-15b and the 4th for miR-503, which we 
69 previously  found  to  be  increased  in  diabetic  CLI23.  The  relative  expression  of  the  four 
70 individual miRs in human limb muscles is reported in Figure 1E. Considering these data, we 
71 focussed the study on miR-15a and miR-16. To investigate whether miR-15a and -16 
72 expression is regulated by limb ischemia, we harvested mouse adductor and gastrocnemius 
73 muscles at 1 and 3 days, post-femoral artery ligation or sham-operation, and we measured 
74 miR expression in the whole tissues and in muscle CD146+ microvascular cells. Ischemia- 
75 associated expressional changes in the whole muscles were limited to miR-15a (Figure 2A). 
76 However, both miRs were increased in the ischemic microvascular cells (Figure 2B). 
 
77 We next moved to model the ischemic environment in vitro, by exposing cultured human 
78 umbilical vein EC (HUVECs) to either oxygen or nutrient deprivation. When combined, hypoxia 
79 (1% pO2) and serum starvation increased the expression of the prototypical “hypoxamiR” 
80 proangiogenic miR-21030 (Supplemental Figure S1), used here as a positive control to validate 
81 the culture conditions. The expression of miR-16 was also increased, while miR-15a was 
82 unchanged. Taking each condition separately, hypoxia alone increased miR-210 expression, 
83 but it did not affect miR-15a/16 levels (Supplemental Figure S2A-C). By contrast, serum 
84 deprivation for 24h increased the expression of both miR-15a and -16 levels (Supplemental 
85 Figure S2D-E). As expected, miR-210 expression was unaffected by serum starvation 
86 (Supplemental Figure S2F). As shown in Supplemental Figure S3, the serum starvation- 
87 induced expressional changes were limited to the mature forms of miR-15a and-16 and 
88 neither the primary transcript (pri-miR-15a/16-1) or the individual miR precursors (pre-miR- 
89 15a, pre-miR-16-1, pre-miR-16-2) were affected. 
 
90 miR-15a and -16 target Tie2 in CDS, and Tie2 repression mediates the anti-angiogenic 
91 responses to miR-15a and -16 
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92 MiR-16 has already been shown to inhibit the angiogenic potential of HUVECs18. Using a 2D 
93 Matrigel assay, we have confirmed these data and additionally characterized that miR-15a 
94 inhibits angiogenesis in vitro (Supplemental Figure S4). Next, we set out to investigate the miR 
95 putative target genes that could elucidate the anti-angiogenesis response. In previous studies, 
96 bioinformatic predictions assuming miRs targeting the 3’UTR of mRNAs, have identified VEGF- 
97 R2, FGF-R1, VEGF-A, FGF-1, FGF-2 and AKT-3 to be repressed by miR-15/1618, 20, 31, 32. More 
98 recently, members of miR-16 family have been shown to bind in the CDS region of their 
99 targeted mRNAs11, 33, 34. Therefore, we expanded our search to putative miR binding sites in 
100 the CDS of proangiogenic genes. A genome-wide prediction using miRcode revealed 12,269 
101 common targets of miR15a and -16. To identify GO terms and processes that these common 
102 targets correspond to, a GO enrichment analysis was performed using the program CLUEGO. 
103 Overall 48 GO terms were significantly enriched among the common targets of miR-15a and 
104 -16. The top 15 of the GO terms for these predicted targets included “blood vessel 
105 development” (Supplemental Figure S5A). From this search, TEK (aka, Tie2 angiopoietin 
106 receptor) was declared an interesting candidate, because it is one of the most studied 
107 regulators of angiogenesis35. Four angiopoietin (Ang) ligands can bind to Tie236. Amongst 
108 them, the most studied are Ang1 and Ang2. Ang1 has a clear agonistic impact on Tie2 and 
109 promotes angiogenesis and vessel stability. The type of interaction of Ang2 and Tie-2 and 
110 vascular  consequences  are  more  debated  and  context-dependant36-38.  Ang-2  has  been 
111 reported increased by inflammatory and hypoxic stimuli and to promote neoangiogenesis39. 
112 However, Ang2 can also disrupt the connections between the endothelium and perivascular 
113 cells and promote cell death and vascular regression38, 40. We decided to focus on TEK because 
114 a closer inspection of the miRcode results revealed that there is only one binding site for miR- 
115 15a and -16 in the CDS region of TEK and no binding sites in the 3’ or 5’UTR. This implied that 
116 the possible direct regulatory action of miR-15a and miR-16 on TEK are exclusively mediated 
117 via miR binding in CDS. In more detail, this single binding site is a 6 bp region and the exact 
118 location is at chr9: 27204938 – 27204943 (Supplemental Figure S5B). This site is  highly 
119 conserved in mammals (83%) followed by primates (67%) and vertebrates (46%) 
120 (Supplemental Figure S5C). Next, to validate the direct binding of miR-15a or miR-16 to this 
121 CDS of Tie2 mRNA, we developed a luciferase reporter assay in which a sequence of 50 
122 nucleotides either side  of the  predicted  binding site of miR-15a-16 on TEK (LUC-TEK), or to 
123 the same sequence but where the binding site was mutated (LUC-TEKmut,) was cloned 
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124 downstream of luciferase gene (Figure 3A). In HeLa cells carrying LUC-TEK, overexpression of 
125 miR-15a and/or miR-16 by pre-miR transfection decreased luciferase activity. This response 
126 was not observed if cells were carrying LUC-TEKmut (Figure 3A). To obtain evidence of the 
127 consequence of Tie2 targeting by miR-15/16 for angiogenesis, we next moved to HUVECs. In 
128 HUVECs  transfected  to  overexpress  either  miR-15a  or  miR-16  (Figure  3B),  Tie2  mRNA 
129 expression was increased (Figure 3C), while Tie2 protein level was decreased (Figure 3D); 
130 consistent with the notion that miR binding to the mRNA CDS leads to RNA translation 
131 inhibition41. Conversely, inhibition of miR-15a and -16 using anti-miRs increased Tie2 protein 
132 expression (Figure 3E). This was associated with a proportional increase in Tie2 
133 phosphorylation, indicating that Tie2 receptors released from the miR inhibitory block were 
134 functionally active42 (Supplemental Figure S6). The importance of Tie2 in mediating the 
135 antiangiogenic effect of either miR-15a or miR-16 was finally confirmed by using a 
136 pharmacological inhibitor of Tie2 activity43. Tie2 inhibition prevented the proangiogenic 
137 response to inhibition of either anti-miR-15a or anti-miR-16 (Figure 3F). To understand 
138 whether the expression of miR-15a and -16 and Tie2 are correlated in ischemic limb muscles 
139 and their microvascular cells, we measured Tie2 expression in similar conditions by RT-PCR 
140 and by immunohistochemistry. While miR-15a and -16 were increased by ischemia (Figure 
141 2A-B), Tie2 protein level was unchanged in ischemic capillaries (Supplemental Figure S7A-H) 
142 suggesting that additional molecular mechanisms are responsible for Tie2 expressional 
143 regulation. Ang1 expression was not changed in muscles at 1 and 3 days, post-ischemia. By 
144 contrast, Ang2 increased at 3 days, post-ischemia (Supplemental Figure S7A-B). 
 
145 Ad.Luc-miR-15a/16 Decoy can be used to sense expressional changes in miR-15a and -16 
 
146 We next prepared Luc-Decoy in the form of a miR decoy system linked to a luciferase reporter 
147 gene (Supplemental Figure S8A), with the intention to both “sense” changes in endogenous 
148 miR-15a and -16 levels and inhibit the functionality of miR-15a/16 in cultured cells and in 
149 murine ischemic limb muscles. The capacity of this tool to sequester the endogenous miR, 
150 thus inhibiting miR activity, was already proven in our previous publications on miR-50323, 24. 
151 Here, we additionally evaluated whether Ad.Luc-miR-15a/16 Decoy was useful in tracking 
152 expressional changes in miR-15a and -16 expression in vitro and in vivo. We used HeLa cells 
153 transfected with either pre-miR-15a or pre-miR-16, and infected with either Ad.Luc-Decoy or 
154 Ad-Luc, to validate that increases in intracellular miR-15a and -16 reduce luciferase activity 
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155 detected in an IVIS apparatus (Supplemental Figure S8B). Importantly, we could confirm that 
156 Ad.Luc-Decoy was selectively sensing changes in miR-15a and -16 in comparison with other 
157 miR-16 family members, such as miR-15b and miR-503 (Supplemental Figure S8C). We next 
158 investigated  whether  the  Ad.Luc-Decoy  system  could  be  used  to  sense  increases  in 
159 endogenous miR-15a and -16 expression. To this aim, HUVECs were infected with Ad.Luc- 
160 Decoy or Ad.Luc and submitted to serum withdrawal. After 24 h, we found a decrease in 
161 luciferase activity in cells infected with Ad.Luc-Decoy in comparison to cells infected with 
162 Ad.Luc control (Figure 4A). We then evaluated the effect of Ad.Luc-Decoy injection into 
163 murine muscles after induction of limb ischemia in vivo. At one day post-LI, in keeping with 
164 the increased miR-15a and -16 expression in total ischemic muscle (see Figure 2A), the 
165 luciferase activity was reduced in mice injected with Ad.Luc-Decoy compared with mice 
166 injected with the control virus (Figure 4B-C). A reduction in luciferase activity was also 
167 observed at day 21, when miR-16 was found upregulated in ischemic muscle (Supplemental 
168 Figure S9). Figure 4D summarizes the modality of action and potential of Ad.Luc-Decoy. 
 
169 Ad.Luc-Decoy improves post-ischemic blood flow recovery and therapeutic angiogenesis 
 
170 We finally provided evidence of the therapeutic potential of Ad.Luc-Decoy in the mouse limb 
171 ischemia model. When compared with Ad.Luc, Ad.Luc-Decoy improved post-ischemic blood 
172 flow recovery (Figure 5A-B) and increased the reparative angiogenesis response in the 
173 ischemic muscles (Figure 5C-D). The latter was demonstrated by a 35% increase in capillary 
174 density (CD31+ capillaries) and 47% increase in the density of small (lumen diameter <20 µm) 
175 arterioles (Figures 5C-D) in the ischemic muscles. Similar post-ischemic increase of capillary 
176 density was found using Isolectin B4 as a marker for endothelial cells (Ad.Luc versus Ad.Luc- 
177 Decoy at 21 days post-ischemia : 557±69 versus 812±97 capillaries per mm2 (mean±sem). 
178 Using toe necrosis as a marker of ischemia severity44, we showed that Ad.Luc-Decoy improved 
179 toe survival (Figure 5E). Finally, in line with in vitro data reported in Figure 3C-D, Ad.Luc-Decoy 
180 increased Tie2 protein expression (Figure 5F) and did not change the expression of Tie2 
181 ligands, Ang1 and Ang2 (Supplemental Figure S10). The mRNA expression of VEGF-A, VEGF- 
182 R2, FGF-2, FGF-1, which were all described to be bound in their 3’UTR by miR-15a or -16, were 
183 also unchanged (Supplemental Figure S11). 
 
184 
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185 Discussion 
 
186 This study has characterized the expressional regulation of miR-15a and -16 in ischemic ECs 
187 and identified that the antiangiogenic actions of these miRs is in part mediated by repression 
188 of Tie2. Additionally, we have utilized a miR decoy approach to sense and inhibit the activity 
189 of endogenous miR-15a and -16 in cultured cells and mouse ischemic muscles. In vivo work 
190 has provided evidence of the therapeutic potential of Ad.Luc-Decoy in CLI. 
 
191 MiR-15a and -16 were previously described to be expressed in various solid and blood 
192 cancers45, 46. Additionally, the group of Eva Van Rooij has studied miR-15 in the ischemic heart, 
193 showing  that  it  induces  cell  cycle  arrest  in  neonatal  cardiomyocytes  and  contributes to 
194 ischemic damage of the heart in adult rodent and swine models47, 48. Early in this study, we 
195 found that under basal conditions, comparing several human organs and tissues, miR-16 and 
196 especially miR-15a are more highly expressed in the skeletal muscle compared to the heart. 
197 To the best of our knowledge, the consequences of endogenous changes in miR-15a and -16 
198 in limb ischemia, and their possible impact on post-ischemic vascular responses, have never 
199 been directly investigated. However, we previously reported increased serum levels of miR- 
200 15a and 16 in diabetic CLI patients, where circulating miR-15a and -16 level were able to 
201 predict clinical outcome (amputation) at 12 months post-revascularization20. In this new 
202 study, we have been able to show that limb ischemia increases miR-15a and -16 in the 
203 muscular microvascular cells, and that the ischemia-induced increase of these endogenous 
204 miRs impairs post-ischemic vascular repair, worsening  blood flow recovery and toe survival. 
205 It should be noted that under our ethics license, we are not allowed to study more severe 
206 forms of limb ischemia outcome and we must humanely euthanize our research animals, if 
207 these occur. The angiogenic response observed in mice after local delivery of Ad.Luc-Decoy is 
208 in line with our previous work on human proangiogenic circulating cells (PACs), which were 
209 shown to carry higher miR-15a and -16 levels when obtained from CLI patients. Moreover, 
210 PACs improved their pro-angiogenic profile when ex vivo simultaneously transfected with 
211 inhibitors for the two miRNAs before their efficacy testing in immunosuppressed mice with 
212 limb ischemia20. Similar to the limb ischemia setting, miR-15a is elevated in the ischemic 
213 heart48. In contrast, hypoxic cancer tissues expressed less miR-15a/miR-16 than non-hypoxic 
214 ones49. MiR-15/16 function as a tumour suppressor by targeting BCL245. They also inhibit 
215 cancer angiogenesis by targeting FGF-249. Therefore, in cancer, miR-15/16 expression 
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216 deregulation might contribute to explain why hypoxia, a common micro-environmental 
217 feature of rapidly growing tumours, is associated with worse clinical outcomes50. According 
218 to our data, in ischemic non-cancerous ECs, the regulation of miR-15a and 16 expression is 
219 hypoxia-independent  and  triggered  by  nutrient  deprivation.  We  have  also  clarified that 
220 increases in mature miR-15a and -16 are not associated with equivalent changes in primary 
221 or precursor miR expression and hence are possibly due to either slower miR decay or 
222 accelerated maturation of the premiRs to mature miRs. 
223 
224 This study has newly identified Tie2 as a target of miR-15a and -16. The angiopoietin Tie2 
225 receptor is mainly expressed in the vascular endothelium and involved in embryonic and post- 
226 natal blood vessel development51, 52. Interestingly, we found that Ang2 was upregulated in 
227 ischemic muscles, while Ang1 was unchanged. Tie2 levels were also unchanged by ischemia. 
228 The modality of action of Ang2 on Tie2 is still debated and has been suggested to function as 
229 a context-dependent agonist/antagonist42 and to be associated with inflammatory 
230 responses53. Direct intramuscular injection of plasmid DNA encoding Ang1 but not Ang2 was 
231 shown to augment revascularization in a rabbit ischemic hindlimb model54. Increasing the 
232 Ang1/Tie2 signalling in ischemic limb muscles could be beneficial for reparative angiogenesis. 
233 In fact, Tie2 disruption was shown to impair post-ischemic regeneration in mice with limb 
234 ischemia55. This is in line with our data showing that Ad.Luc-Decoy-induced increase in limb 
235 Tie2 is associated with improved post-ischemic reparative angiogenesis and blood flow 
236 recovery. We have clarified that miR-15a/-16 binds to the CDS of Tie2. A few studies have 
237 started to report efficient targeting of miRs on CDS. The canonical mechanism of action of a 
238 miR involves the stabilization of mature miR by Argonaute-2 (Ago2) proteins, functioning to 
239 direct the RISC (RNA-induced silencing complex) to target mRNAs. According to this model, 
240 binding between the miR seed sequence to one or more semi-complementary regions within 
241 the mRNA 3’UTR induces post-transcriptional inhibition, manifesting as reduced mRNA and 
242 protein levels11. It is progressively emerging that this model is probably insufficient to explain 
243 miR actions, and that in some cases the most predominant Ago2:miR-binding sites may be 
244 found within the coding sequence (CDS)11. It has already been shown that miR-103 and -107, 
245 which belong to the wider miR-16 family, do make ample use of CDS targeting34. The miR 
246 target sites in the CDS are under evolutionary selection41. Sequence conservation has usually 
247 been taken as evidence of functional importance56, 57. In this context, it is of interest that the 
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248 miR-15a/16 binding sites to CDS targets are conserved between species (human and 
249 macaque58). MiR-15a/b and -16 contain the AGCAGC motif at the 5′ end. Using computational 
250 analyses, Hausser et al found that miRNAs with this motif location have more complementary 
251 sites in the CDS compared with 3′ UTR. Such miRNAs also have in common the capacity to 
252 regulate the cell cycle41. Hausser et al additionally suggested that CDS binding is more potent 
253 in inhibiting mRNA translation, as compared to mRNA degradation. This is consistent with our 
254 finding that premiR-15a or -16 transfection of HUVECs reduced protein and increased mRNA 
255 expression for Tie2. In our study we used an “homology of sequence” strategy to identify miR- 
256 15a and -16 mRNA targets. MiR-mRNA interactions are largely based on sequence homology, 
257 but are also dependent on additional factors. As an example, mRNA 3D configuration can 
258 affect the accessibility of the RISC complex binding site 59. Increasing evidence shows that 
259 binding of a miR to its mRNA targets can be cell-type and environment-dependent60 and that 
260 this can be relevant for anti-miR cardiovascular therapies61. This was already exemplified by 
261 Eding et al61, who found that upon in vivo inhibition of the cardiomyocyte-specific miR-208a, 
262 the quality and quantity of direct targets of miR-208a that are expressionally modulated, 
263 depend on the presence and type of cardiac stresses such as hypertension or myocardial 
264 infarct. The anti-miR-208 treatment in healthy and diseased hearts revealed 3 subsets of 
265 targets: 1) health-specific targets, 2) disease-specific targets, 3) targets common to health and 
266 disease. In line with that, we have also noted a context-dependent target regulation after 
267 inhibition of miRNA-15a and 16. In fact, Chamorro-Jorganes et al showed that miR-16 
268 regulates VEGFR2 in human ECs cultured under normal conditions18. In our model of limb 
269 ischemia, miR-15a/16 inhibition using the Ad.Luc-decoy virus did not change the expression 
270 of VEGF-R2 or other previously described targets of miR-15a or -16, such as VEGF-A, FGF-1 
271 and FGF-218, 20, 32. 
272 
273 We have shown that viral vector-mediated local delivery of a miR decoy increases the density 
274 of small arterioles, which contain vascular smooth muscle cells (VSMC) and play an important 
275 role in resistance of blood flow in skeletal muscles62, 63. The data presented here are 
276 consistent with our previous report that miR-15a decreased human VSMCs migration and 
277 proliferation in vitro20, biological process involved in arteriole growth64. 
278  
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279 Our study also showed the potential of using a bioluminescence IVIS apparatus to non- 
280 invasively detect changes in endogenous miR expression in wild type animals. Conventional 
281 techniques to measure miR expression usually consist of RT-PCR, microarray analyses and 
282 Northern blots. Even though these techniques are accurate, they require lysed cells or tissues 
283 that represent a further constraint for time course studies, especially in vivo 65. A major 
284 strength versus genome editing of small animal models, which is otherwise possible, is that, 
285 once optimised, it can be translated for use in large animal models and human patients. In 
286 future studies, the prototypical Ad.Luc-Decoy can be refined to increase precision of 
287 measurements of different miR types and it can be adapted for use with different viral 
288 vectors, with different tropism and length of transgene expression. 
 
289 Finally, this study has provided the first evidence that local inhibition of miR-15a/-16 is 
290 effective in improving post-ischemic vascular repair in limbs. This finding has translational 
291 implications, and significantly expands on what has already been reported by Hullinger et al 
292 in heart ischemia models, where locked nucleic acid (LNA)-modified anti-miR was  employed 
293 to target miR-15, reducing infarct size. Hullinger et al focussed exclusively on the heart and 
294 did not investigate the vascular response to miR inhibition. Clinical trials based on LNA  have 
295 already started in patients with different forms of lymphoma and leukaemia 
296 (https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/lna-based- 
297 antimir-155-mrg-106). Additionally, gene therapy clinical trials to test proangiogenic 
298 therapies have been already authorised by regulatory authorities66. Therefore, our proof of 
299 concept that miR-15a/16 inhibition holds therapeutic potential in the setting of limb ischemia 
300 has the potential to be progressed through the translational pipeline via at least two 
301 alternatives (LNA or viral vector mediated-Decoy transfer) to reach the bedside of CLI 
302 patients. 
 
303  
 
304 Materials and Methods 
 
305 Human RNA tissue bank quantitative Real Time PCR analysis 
306 RNA from a human tissues bank (resulting from the pooling of three samples from different 
307 patients) was obtained from Ambion, Applied Biosystems. Reverse transcription was 
308 performed using the TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems, 
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309 #4366596) and Real-time PCR were performed in triplicate using the TaqMan universal 
310 master mix with the LightCycler480 qPCR detection system (Roche, #04707516001). 
311 Expression  was  normalized  to  the  small nucleolar  RNA  U6 (snRU6). Primer  identification 
312 numbers are indicated in Supplemental Table 1. Relative miRNA expression was defined from 
313 threshold cycle (Ct) values, calculated using the 2(-ΔΔCt) method. 
314  
315 Mouse Limb Ischemia model 
316 The experiments involving mice were performed in accordance with the Guide for the Care 
317 and Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources and 
318 with the prior approval of the UK Home Office and the University of Bristol ethics committee. 
319 Sample size was determined using a power calculation with blood flow at 21 days, post- 
320 ischemia, measured using laser Doppler, as the primary outcome. Specifically, for an 80% 
321 power at a 5% significance level, to detect a 50% increase in ischemic:contralateral limb blood 
322 flow ratio (see below) in the test group (from a mean of 0.4 to 0.6, based on previous 
323 experience), at least 12 mice were required in each group. Based on our own pilot data on 
324 the use of in vivo bioluminescence analyses, this number of mice would give us a 90% power 
325 to detect a three-fold difference in bioluminescence activity. Left limb ischemia (LI) was 
326 induced in 10-12 week-old CD1 male mice (Charles River, Margate, UK). Mice were 
327 anesthetized (tribromoethanol, 880 mmol/kg i.p., Sigma-Aldrich, #T48402) and the left 
328 femoral artery ligated with a 6-0 silk suture at two points, followed by electrocoagulation of 
329 the ligated segment, leaving the femoral vein and nerve untouched67. Analgesia (Vetergesic, 
330 0.02 ml/30 g animals) was administrated after surgery. Mice were excluded, and humanely 
331 euthanized, where they developed signs or symptoms of severe limb ischaemia, as per the 
332 conditions of our ethics license. Any data accrued for excluded mice were still analysed up to 
333 the point of exclusion. In vivo experiments were performed by three investigators (SS, LH, 
334 ACT). Where experiments involved the randomization of mice into one of two groups, the 
335 operator and outcome assessor were blinded as to the group allocation. For evaluation of 
336 miR-15a/-16 expression in ischemic muscles, mice were sacrificed at 1 and 3 days after 
337 surgery. Ischemic and contralateral adductor muscles were harvested and RNA extraction was 
338 performed on either the total muscle or muscle CD146+ microvascular cells extracted 
339 following a previously described protocol68. 
340  
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341 RNA extraction from mouse tissue and cells and quantitative real-time PCR analysis 
342 Total RNA was extracted from adductor muscle tissues and mouse cells using miRNeasy Mini 
343 Kit (Qiagen, #217004) according to the manufacturer’s instructions. RT-PCR was performed in 
344 triplicate as described above. 
345  
346 Cell culture 
347 Human umbilical cord vein endothelial cells (HUVECs, Lonza, Slough, UK, #CC-2519) were 
348 cultured between passage 2 and 6, at 37 °C with 5% CO2 in EBM-2 endothelial cell basal 
349 medium (Lonza, #CC-3156) with addition of the SingleQuot Kit (EGM-2 medium, Lonza, #CC- 
350 4176) containing 2% fetal bovine serum (FBS, included in the kit). For hypoxia experiments, 
351 cells were exposed to 1% pO2 for 24 and 48 h, whereas for the normoxia control condition, 
352 cells were exposed to 21% pO2. For the serum deprivation condition experiments, cells were 
353 cultured in EGM-2 medium without FBS for 24 and 48 h, whereas in the control condition, 
354 cells were exposed to complete medium. HeLa cells were maintained in Dulbecco’s Modified 
355 Eagle’s Medium (DMEM, Invitrogen) supplemented with 10% FBS and 1% 
356 penicillin/streptomycin (Gibco, #15140122). Cells were incubated in a humidified atmosphere 
357 at 37˚C with 5% CO2. 
358  
359 Bioinformatic prediction of new miR-15a and -16 targets 
360 The program miRcode (http://www.mircode.org/index.php) was used to predict common 
361 genome-wide targets of miR-15a and miR-16 by looking for their binding sites in the 3’UTR, 
362 5’UTR and CDS regions of human genes. The predicted common targets of the two were then 
363 subjected to a Gene Ontology (GO) analysis to identify enriched terms and processes. GO 
364 analysis was performed using CLUEGO69 with significant terms considered at a Bonferroni- 
365 corrected p-value of ≤ 0.05. 
366  
367 Luciferase Assay for validation of miR-15a and -16 binding to Tie2 mRNA 
368 The binding sequence for the miR-16 family on Tie2 CDS was identified using miRcode 
369 software. The binding site is in position: chr9:27204938-27204943. 450 bps either side of the 
370 binding site was cloned in pMIR-Reporter (Life Technologies). Primers used for the cloning 
371 were as follows: Tie2 CDS, forward 5′- ATAGTGGTTAGGTGGCAGGG-3′, reverse 5′- 
372 CTGCCTGTACTTGGACTTGC-3′; Primers for 3′ UTR mutation were as follows: Tie2 CDS, forward 
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373 5′- AGGGGGGAAGAATAATAAATTAGCCATCCTTGG -3′ and reverse 5′- 
374 CCAAGGATGGCTAATTTATTATTCTTCCCCCCT   -3′.   Luciferase   assays   were   performed   as 
375 previously described24. Briefly, luciferase constructs were transfected into HEK293T cells 
376 together with either miR-15 or/and miR-16 mimics or p-SV-β-gal control vector. Cells were 
377 cultured for 48 h and assayed with the Luciferase and β-Galactosidase Reporter Assay Systems 
378 (Promega, #E1500 and #E2000, respectively) Luciferase values were normalized to protein 
379 concentration and β-galactosidase activity. 
380  
381 Tie2 expression regulation by miR-15a and -16 in HUVECs 
382 HUVECs were plated on a 6 multiwell plate at a density of 2.0 x 105 cells per well in 2 mL EGM- 
383 2 and grown for 24 h until 70–80% confluent. Cells were then washed once with PBS and 
384 maintained in OPTIMEM medium (Invitrogen, #31985062) for 0.5 h prior to transfection with 
385 either pre-miRs (hsa-miR-15a-5p, PM10235; hsa-miR-16-5p, PM10339, Ambion, 5nM), anti- 
386 miRs (MH10339 and MH10235, Ambion, total 50 nM) or a scramble (Scr) control (Cy3 dye- 
387 labeled Pre-miR Negative Control, AM17120 or Anti-miR Negative Control AM17011, Ambion) 
388 using Lipofectamine RNAiMAX (Invitrogen, #13778150), according to the manufacturer’s 
389 protocol. Two days after transfection, cells were lysed either in ice cold Pierce RIPA buffer 
390 (Thermoscientific,  #89900)  completed  with  cOmplete  Protease  Inhibitor  Cocktail (Roche, 
391 #11697498001)  and  phosphatase  inhibitor  PhosSTOP  (Roche,  #4906845001)  for  protein 
392 extraction,  or  with QIAzol  for  RNA  extraction  (miRNeasy  Mini  Kit,  #217004). For reverse 
393 transcription, cDNA was synthesised from 500 ng of total RNA using the QuantiTect RT kit 
394 (Qiagen, Manchester, UK, #205314), as per the manufacturer’s instructions, including a step 
395 to remove genomic DNA. All cDNA was stored at -20°C. Quantitative PCR was performed using 
396 Power SYBR (Life Technologies, Paisley, UK, #4368708) with a QuantStudio 6 Flex Real-Time 
397 PCR System (ThermoFischer Scientific), according to the manufacturer’s instructions. Primers 
398 used to measure expression of human Tie2 are indicated in Supplemental Table 2. Data were 
399 normalized to 18S as an endogenous housekeeping gene, and relative expression was 
400 calculated using the 2-(ΔΔCT) method. To extract protein, lysates were incubated at 4°C on a 
401 rotator. Samples were centrifuged at 14,000 × g for 15 min at 4°C, and the supernatant 
402 fractions were used for western blot. Protein concentration was determined using the 
403 Pierce™ BCA Protein Assay Kit (ThermoFischer Scientific, #23225). Detection of proteins by 
404 western blot analyses was done using 10 μg of protein extract on SDS-polyacrylamide gels. 
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405 Proteins were transferred to nitrocellulose membranes and probed with the following 
406 antibodies: Goat anti-human Tie2 (RnD Systems, AF313, 1:1000), Rabbit anti-human/mouse 
407 phospho-Tie2 (Y992) (RnD Systems, AF2720, 1:3000) and mouse and human β-Actin  (Sigma, 
408 A5441; 1:50,000). Secondaries antibodies used were  ECL mouse IgG (GE Healthcare, NA931; 
409 1:5000), mouse anti-goat-HRP (SantaCruz, sc-2354, 1:2000) and donkey anti-rabbit-HRP 
410 (SantaCruz, sc-2313, 1:2000). Membranes were stripped between imaging of phospho-Tie2 
411 and total Tie2. 
412  
413 Matrigel assay of HUVECs transfected with miR-15a and miR-16 inhibitors and Tie2 inhibition 
414 HUVECs were transfected using Lipofectamine RNAiMAX  (Invitrogen, #13778150) and  Anti- 
415 miR Negative Control, anti-miR-15a or miR-16 inhibitors following the protocol described 
416 above. The cells were used for Matrigel assay at 48h after transfection. On the day of the 
417 Matrigel assay, HUVECs were plated onto duplicate wells containing 70 μl of Reduced Growth 
418 Factors Matrigel (BD Biosciences, #356231), on a 96-well plate (104 cells/well) in complete 
419 medium with or without 5 µM of Tie2 inhibitor (ab141270, Abcam) or the equivalent volume 
420 of the inhibitor diluent (DMSO, final concentration 0.05%). The experiment continued for 24h 
421 before imaging each well at x5. Network formation was quantified in randomly captured 
422 microscopic fields by calculating the length of cellular network using Image-Pro plus software. 
423  
424 Ad.Luc-Decoy 
425 The fragment of firefly luciferase-decoy 15-16 (Luc-Decoy) under the control of the 
426 Cytomegalovirus (CMV) promoter (2662 base pairs) was excised from TW-3’UTR LUC DEC15- 
427 CYAN70 with ClaI and EcoRV , blunt ended using mung bean nuclease and ligated into pDC511 
428 shuttle vector (Microbix Biosystems, Canada). Replication-deficient E1-E3 deleted adenovirus 
429 were generated by recombination in 293 cells71. The DNA construct consists of the CMV 
430 promotor followed by a luciferase gene and tandem sequences complementary to miR-15a 
431 and also 80% complementary to miR-16 (decoy sequences) separated by a 18 bp unrelated 
432 spacer70. 
433  
434 Preparation of HeLa cells and HUVECs for in vitro bioluminescence analyses using the IVIS 
435 system 
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436 HeLa cells were seeded on a T75 flask at a density of 8 x 105 per flask in 10 mL complete 
437 DMEM and grown 24 h until 70–80% confluent. Cells were then infected overnight with 
438 Ad.Luc-Decoy virus at 10 multiplicity of infection (MOI) in DMEM without FBS. To transfect 
439 the cells with miR precursors, HeLa cells were plated in duplicate on a 6-well plate at a density 
440 of 2.5 x 105 cells per well in 2 mL DMEM 10% FBS and grown for 24 hours until 70–80% 
441 confluent. Cells were then maintained in OPTIMEM medium (Invitrogen, #31985062) for 30 
442 min prior to transfection with 25 nM of pre-miR-15a, pre-miR-16 or Scr. For luciferase activity 
443 measurement, after transfection, HeLa cells were plated in a 96-well plate at a density of 1 x 
444 103, 2 x 103, 4 x 103, 6 x 103, 8 x 103, 1 x 104, 2 x 104 and 3 x 104 cells/well in duplicates. After 
445 12 h, the medium was removed and replaced by 100 µL of pre-warmed PBS containing 
446 150µL/mL of D-Luciferin (Caliper LifeSciences, #122796). Luciferase activity was measured 1 
447 min after addition of the D-Luciferin using an In Vivo Imaging System (IVIS). The average of 
448 n=2 per condition plated in duplicate was then expressed in units of maximum photons per 
449 second per centimetre-squared per steradian (P. s-1. cm-2.sr-1). 
 
450 HUVECs were seeded on a 12-well plate at a density of 1 x 105 per well in 1 mL complete EGM- 
451 2  medium  and  grown  until  70–80%  confluent.  Cells  were  then  infected  overnight with 
452 adenoviruses Ad.Luc-Decoy or Ad.Luc at 100 multiplicity of infection (MOI) in EGM-2 complete 
453 medium. The following day, the cells were washed with PBS and the medium replaced with 
454 normal complete or serum free EGM-2 medium for 24 h. After luciferase activity 
455 measurement (performed as in HeLa cells), HUVECs were then trypsinized and counted. The 
456 average of n=5 per condition was then expressed in units of maximum photons per second 
457 per centimetre squared per steradian (P. s-1. cm-2.sr-1) per cell. 
 
458 Preparation of mice for in vivo bioluminescence analyses using the IVIS system 
459 The sample size for in vivo work was based on power calculations. Mice were randomized in 
460 two treatment groups (n=14 mice per group) and underwent limb ischemia induction. 
461 Immediately after the procedure, Ad.Luc-Decoy or Ad.Luc (109 plaque forming units per 
462 mouse in a total volume of 30 µL injected into 3 equidistant sites) were delivered to the 
463 ischemic adductor muscle. The luciferase activity in the ischemic muscles was evaluated at 1, 
464 3, 7 and 21 days, post-surgery using the Xenogen In Vivo Imaging System. Following the 
465 exclusion criterion stated above, the day 21 analysis included 12 mice in the Ad.Luc-Decoy 
466 group and 10 in the Ad.Luc group. Briefly, after anaesthesia induction (tribromoethanol, 880 
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467 mmol/kg i.p., Sigma-Aldrich, #T48402), the mouse ischemic leg was injected subcutaneously 
468 with the reporter probe D-luciferin (Caliper LifeScience, #122796) at 150 mg/kg body weight. 
469 After 10 minutes, animals were imaged. Bioluminescence was quantified and expressed in 
470 units of maximum photons per second per centimetre-squared per steradian (P. s-1. cm-2.sr- 
471 1), as described previously72. 
472  
473 Efficacy testing the therapeutic potential of Ad.Luc-Decoy 
474 The mice used for the IVIS analyses were tested for post-ischemic blood flow recovery, 
475 therapeutic angiogenesis and clinical outcome in terms of toe necrosis. The superficial blood 
476 flow (BF) of the ischemic and contralateral foot was sequentially analysed, starting 
477 immediately after surgery and at 7, 14, and 21 days, using a high-resolution laser colour 
478 Doppler imaging system (Moor LDI2, Moor Instruments, Devon, UK). The ratio between BF in 
479 the ischemic and contralateral foot was calculated and used as an index of percentage BF 
480 recovery. At 21 days post-ischemia, mice were perfusion-fixed under terminal anaesthesia, 
481 and adductors were harvested and paraffin-embedded for histological and 
482 immunohistochemical analyses, as previously described67. Toe necrosis occurrence, defined 
483 as darkening of the toe followed by loss of the tissue, was evaluated along the limb ischemia 
484 protocol. The cumulative proportion of toe survival at 7, 14 and 21 days after induction of 
485 limb ischemia was calculated, excluding mice that showed symptoms of femoral nerve 
486 damage. 
487  
488 Histology and Immunohistochemistry on muscles 
489 Four-µm-thick adductor muscles slices were stained using Rabbit anti-mouse/human CD31 
490 (Abcam, ab28364, 1:50) and Donkey anti-rabbit Alexa-647 (Jackson Immunoresearch, 711- 
491 605-152, 1:200) to detect ECs, and with a Cy3-conjugated rabbit polyclonal anti-α-smooth 
492 muscle actin antibody (Sigma, #C6198, 1:400) to stain vascular smooth muscle cells, present 
493 in arterioles. The slides were then mounted using a mounting medium (Fluoromount G, South 
494 Biotech,  #0100-01)  containing  DAPI  (4′,6-diamidino-2-phenylindole)  to  stain  nuclei.   The 
495 number of capillary and arterioles per mm2 was counted in 10 randomly selected high-power 
496 fields (magnification 40×) using a Zeiss inverted fluorescent microscope. The lumen diameter 
497 of α-smooth muscle actin positive arterioles was measured using ImageJ software. Tie2 
498 staining in non-ischemic and ischemic muscles was performed using a mouse anti- 
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499 mouse/human Tie2 antibody (Abcam, ab24859 [Cl. 16], 1:50) and a goat anti-mouse Alexa- 
500 568 (Abcam, ab175473, 1:200) on cryosections. At least 5 fields of magnification 40x using 
501 Zeiss AxioObserver inverted fluorescent microscope were used to analyse the percentage of 
502 Tie2+/CD31+ capillaries. Intensity of staining of Tie2 within the Tie2+/CD31+ capillaries was 
503 analysed using Fiji software. 
504  
505 Tie2 expression in ischaemic skeletal muscle injected with Ad.Luc and Ad.Luc-Decoy virus: 
506 Animal received surgery of limb ischaemia and were injected into the adductor muscle with 
507 109 pfu per animal with either Ad.Luc or Ad.Luc-Decoy. Three days after surgery, animals were 
508 euthanised and ischaemic muscles were collected and snap-frozen. Tissues were 
509 mechanically disrupted either in Qiazol (Qiagen) for RNA extraction or in RIPA buffer 
510 (Thermoscientific, # 89900) completed with cOmplete protease inhibitor cocktail and 
511 phosphatase inhibitor PhosSTOP for protein extraction as described above. Total RNA from 
512 adductor muscle tissues was extracted using miRNeasy Mini extraction Kit (Qiagen, #217004) 
513 according to the manufacturer’s instructions. For tissues collected at 21 days post-LI, total 
514 RNA from formalin-fixed and paraffin-embedded tissue sections was isolated using 
515 deparaffinization solution and miRNeasy FFPE Kit (Qiagen #217504) according to the 
516 manufacturer’s protocol (deparaffinization solution : #19093). For mRNA analysis, reverse 
517 transcription was performed using the QuantiTect Reverse Transcription kit (Qiagen, # 
518 205314), according to the manufacturers’ protocols. cDNA was amplified by quantitative real- 
519 time PCR (qPCR). cDNA (equivalent to 1 µg total RNA) was incubated in triplicate with gene- 
520 specific primers for mouse Angiopoietin-1, Angiopoetin-2, FGF-2, FGF-1, VEGF-A, VEGF-R2, 
521 Tie2, GAPDH and 18S (sequences presented in Table 2). To extract protein, lysates were 
522 incubated at 4°C on a rotator. Samples were centrifuged at 14,000 × g for 15 min at 4°C, and 
523 the supernatant fractions were used for western blot. Protein concentration was determined 
524 using the Pierce™ BCA Protein Assay Kit (ThermoFischer Scientific, # 23225). Detection of 
525 proteins by western blot analyses was done using 30μg of protein extract on SDS- 
526 polyacrylamide  gels  for  Tie2  and  120μg  for  VEGF-R2.  Proteins  were  transferred  to 
527 nitrocellulose membranes and probed with the following antibodies: goat anti-mouse/rat 
528 Tie2 (RnD Systems, AF762, 1:1000), rabbit anti-human/mouse VEGF-R2 (Abcam, ab39256) 
529 and rabbit anti-mouse α/β-Tubulin (RnD Systems, 2148S; 1:2000). Secondary antibodies used 
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530 were mouse anti-goat-HRP (SantaCruz, sc-2354, 1:2000) and donkey anti-rabbit-HRP 
531 (SantaCruz, sc-2313, 1:2000). 
532 
533 Statistical analysis 
534 Results are presented as mean ± standard error (SEM). Tests for statistical significance were 
535 conducted using GraphPad Prism (version 6; GraphPad Software, San Diego, CA). 
536 Comparisons between two groups were performed using Student’s t-test, with the exception 
537 of the analysis of the capillary and arteriole density for which a Welch's unequal variances t- 
538 test was used. For comparison among more than two groups, ANOVA followed by a Tukey 
539 post-hoc test was used. Differences in necrosis outcomes were assessed using the log-rank 
540 test. Exceptions are indicated in the captions. A p value of <0.05 was interpreted to be of 
541 statistical significance. 
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Figure 1: miR-15a, -15b, -16 and -503 expression in human tissues. 
Expression of miRs in human tissues assessed by RT-PCR (A to D) and relative expression of 
each miR in skeletal muscle (E). Results were normalized to small nuclear RNA U6 (U6) 
expression (n=1/tissue, resulting from the pooling of three different donor samples). 
Figure 2: Expression of miR-15a and -16 is differentially modulated in mouse adductor 
muscles and muscle-derived endothelial cells after limb ischemia. 
At 1 and 3 days after surgical induction of limb ischemia, ischemic and non- 
ischemic/contralateral (control) adductor muscles were collected and the expression of miR- 
15a and -16 assessed by RT-PCR in the total muscle tissue (A) and in muscle-derived CD146+ 
endothelial cells (ECs) (B). Results were normalized to the expression of small nuclear RNA 
U6, relative to control muscle or EC normo-perfused and expressed as mean ± SEM. N=3 per 
condition, **p < 0.01 and ***p < 0.001 versus control, matched for time after ischemia. 
Figure 3: Tie2 is targeted by miR-15a and -16, through an unusual binding site on Tie2 mRNA, 
and is involved in the pro-angiogenic effect of miR-15a and -16 inhibition in HUVECs in vitro. 
(A) Luciferase activity at 48 h post-co-transfection of HEK293T cells with either pre-miR-15a 
(miR-15a), pre-miR-16 (miR-16), a combination of the two (miR-15a/-16), or miR-scrambled 
oligonucleotides (Scr), and plasmid containing luciferase open reading frame (pLUC) followed 
by a portion of 50 nucleotides of the TEK coding sequence, surrounding the putative miR 
binding site (pLUC-TEK). A mutated version of the miR binding site was used as a control 
(pLUC-TEK mut). A schematic of the plasmid construct is also provided. *p < 0.05, ***p < 0.001 
versus pLUC-TEK control Scr; † p < 0.05, †† p < 0.01 versus pLUC-TEK to the pre-miR matching 
condition (n=5). (B) Human Umbilical Vein Endothelial Cells HUVECs were transfected with a 
Scramble oligo (Scr), pre-miR-15a (miR-15a) or pre-miR-16 (miR-16) (5 nM) to increase their 
respective mature miR expression. miR-15a and -16 expressions were assessed by RT-PCR and 
normalized to small nuclear U6 expression. Tie2 mRNA (C) or protein (D) expressions were 
assessed by RT-PCR and western blot, and normalized to 18S and β-actin, respectively. N=3 
for each condition. (E) HUVECs were transfected with a Scramble oligo (Scr) or an anti-miR 
against miR-15a or miR-16, or the two anti-miRs simultaneously (total concentration of 50 
nM) to inhibit their activity. Tie2 protein expression was assessed by western blot and 
normalized to β-actin. N=9 for each condition. * p < 0.05 versus Scr condition. (F) Effect of 
inhibition of Tie2 on miR-15a/-16 inhibition-induced angiogenesis was assessed in Human 
Umbilical Vein Endothelial Cells HUVECs transfected with a Scramble oligo (Scr) or an anti-miR 
against miR-15a or miR-16 (50 nM), and treated with Tie2 inhibitor (Tie2-I, 5 µM) or DMSO 
control. The angiogenic capacity was measured by network formation on Matrigel, calculated 
as total length in mm and expressed as a percentage of the Scr and DMSO conditions. 
Representative pictures are provided (scale bar: 200 µm) N=3. *p < 0.05 , **p < 0.01, ***p < 
0.001. 
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Figure 4: Adenovirus carrying a decoy sequence for miR-15a and -16 (Ad.Luc-Decoy), sensor 
activity and inhibition efficiency in vivo. 
(A) Luciferase activity measured on IVIS of HUVECs infected with Ad.Luc control or Ad.Luc- 
Decoy virus cultured under complete (2% FBS) or serum -deprived (0% FBS) media for 24 h. 
Results are expressed per cell and relative to Ad.-matching, 2% FBS condition. Results are 
presented as the mean of n=4-5 per condition ± SEM. *p < 0.05 , **p < 0.01, ***p < 0.001 
versus Ad.-matching, 2% FBS condition. #p < 0.05 versus Ad.-Luc, 0% FBS condition, Student’s 
t-test. (B-C) After limb ischemia, bioluminescence activity (expressed as photons per second 
per centimetre-squared per steradian (p. s-1. cm-2.sr-1) was measured and analyzed in the 
ischemic legs using the Xenogen In Vivo Imaging System (IVIS). D-Luciferin was 
subcutaneously injected into the ischemic limb, and the consequent bioluminescence from 
the reaction with the luciferase in either Ad.Luc or Ad.Luc-Decoy injected legs was measured 
from day 1 to day 21 after injection of the viruses. Representative images are presented. Data 
are shown as mean ± SEM (n≥10 per condition). *p < 0.05 versus time-matched Ad.Luc 
condition using Student t-test. (D) Schematic explanation of the mechanisms of miR-15a and 
-16 inhibition/trapping and sensing in cells expressing the Luc control construct, lacking 
complementary/decoy sequence for miR-15a/-16, or the Luc-Decoy construct. 
Figure 5: Inhibition of miR-15a/16 improves blood flow (BF) recovery, post-ischemic 
neovascularisation and toe survival, following limb ischemia. 
Limb ischemia was induced in mice by femoral artery ligation, and Ad.Luc or Ad.Luc-Decoy 
were injected into the ischemic adductor muscle immediately after surgery. (A and B) Line 
graph shows the time course of post-ischemic BF recovery (calculated as the ratio between 
the BF of the ischemic foot and the contralateral foot) in mice injected with Ad.Luc or Ad.Luc- 
Decoy. Representative colour laser Doppler images taken at days 0, 7, 14 and 21 post- 
ischemia, are provided. Yellow frames show the ischemic foot analyzed. Data are presented 
as mean ± SEM (n≥10 per group). *p < 0.05, **p < 0.01 versus time-matched Ad.Luc condition. 
(C) Immunohistological analysis and representative microphotographs showing the capillary 
density in mice injected with Ad.Luc or Ad.Luc-Decoy 21 days after LI and in contralateral 
(control) muscle of mice injected with Ad.Luc (n=5 per group) assessed by immunolabelling 
of CD31 as marker of endothelial cells. Scale bar: 50µm. (D) Immunohistological analysis and 
representative microphotographs showing arteriolar density in mice injected with Ad.Luc or 
Ad.Luc-Decoy (n=11 or 8 mice per group, respectively) after limb ischemia, assessed by 
immunolabelling of α-smooth muscle actin (αSMA) as a marker of vascular smooth muscle 
cells. Arterioles were quantified according to vessel diameter (<20 µm or ≥20 µm). Data are 
presented as mean + SEM. Scale bar: 20µm. (E) Cumulative proportion of toe survival over 21 
days of follow-up after ischemia in mice injected with Ad.Luc or Ad.Luc-Decoy (n≥10 mice per 
group). p = 0.0013, log-rank test. (F) Tie2 expression in ischemic adductor muscles, 3 days 
after limb ischemia surgery and injection with either Ad.Luc or Ad.Luc-Decoy virus, was 
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assessed at mRNA and protein level by RT-PCR and western blot, respectively. Results were 
normalized to GAPDH for mRNA analysis (n=6) or to α/β-tubulin for protein analysis (n=9) and 
presented as mean ± SEM. *p < 0.05, versus Ad.Luc group. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPTFigure 1
A)
B)
C)
D)
E)
Sk
ele
tal
 m
us
cle
Sk
ele
tal
 m
us
cle
Sk
ele
tal
 m
us
cle
Sk
ele
tal
 m
us
cle
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPTFigure 2
A)
B)
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPTFigure 3
D)
C)
Tie-2
β-actin
Sc
r
m
iR
-1
5a
Sc
r
m
iR
-1
5a
Sc
r
m
iR
-1
5a
Sc
r
An
ti-
15
a
An
ti-
16
An
ti-
15
a +
 -1
6
Tie-2 ~150KDa
β-actin ~40KDa
E)
m
iR
-1
6
m
iR
-1
6
m
iR
-1
6
~150KDa
~40KDa
Sc
r
Sc
r
Sc
r
F)
D
M
SO
 
Ti
e2
-i 
Scr Anti-15a Anti-16 
B)
A)
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPTFigure 4
A)
D)
A
d.
 L
uc
-
D
ec
oy
Day 1 Day 3 Day 7 Day 21 
A
d.
lu
c
B)
C)
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPTFigure 5
A)
C)
B)
A
d.
Lu
c-
D
ec
oy
Day 1 Day 7 Day 14 Day 21 
A
d.
Lu
c
αSMA
A
d.
 L
uc
A
d.
 L
uc
-D
ec
oy
D)
E)
Tie-2
α/β tubulin
Ad.
Luc
Ad
.Lu
c-D
eco
y
F)
Blood flow recovery
Toe survival
~150KDa
~50KDa
Arteriole density
Day 21 
Day 3 
Capillary density
Day 21 
Ad.Luc
controlateral
non-ischaemic Ad.Luc Ad.Luc-Decoy
Day 21
C
D
31
Ad.Luc Ad. Luc Ad. Luc-Decoy
0
500
1000
1500
*
ca
pi
lla
rie
s/
m
m
2
21 days post-LI
controlateral
non-ischaemic
